Korro bio highlights data for its lead program in alpha-1 antitrypsin deficiency (aatd) and progress across its rna editing portfolio

Cambridge, mass., jan. 18, 2024 (globe newswire) -- korro bio, inc. (korro) (nasdaq: krro), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, presented new data for krro-110 and reported progress across its rna editing portfolio at the j.p. morgan healthcare conference on january 9, 2024.
KRRO Ratings Summary
KRRO Quant Ranking